His Kidney Drug Just Won FDA Approval After Cutting a Key Disease Marker by 43%. One $74,730 Infusion Could Leave Him Owing Nearly $15,000 Under Original Medicare

Published November 15, 2026, 8:04pm ET · 4 min read

The Full Benefits Desk desk. Editor: Gerelyn Terzo.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

asian old man sitting in hospital hallway looking sad and depressed
asian old man sitting in hospital hallway looking sad and depressed © asian old man sitting in hospital hallway looking sad and depressed (Shutterstock.com) by imtmphoto

Consider a hypothetical 67-year-old retiree with IgA nephropathy who has watched protein keep leaking into his urine for two years despite standard therapy. On October 21, 2026, the FDA granted accelerated approval to Ultomiris, developed by Alexion, AstraZeneca’s rare disease division, for adults with primary IgA nephropathy at risk of disease progression. Now his nephrologist wants to talk about it. His first question is what his coverage will pay. He has Original Medicare with no Medigap, no retiree plan and no Medicaid.

For him, one maintenance infusion could leave a bill of nearly $15,000. Enrollees whose Medigap pays the 20% coinsurance, or whose Advantage plan caps it, face a far smaller number. All figures below use the 2026 Part B rules from the Centers for Medicare & Medicaid Services (CMS).

Why a 43% Proteinuria Drop Still Leaves a Question Open

The FDA based the approval on a predefined interim analysis of the I CAN Phase III trial. In that analysis, Ultomiris cut proteinuria by 43.4% versus placebo at 34 weeks. The trial enrolled 584 adults across 28 countries. Their urine protein-to-creatinine ratio fell 46.6% on the drug and 5.6% on placebo. The New England Journal of Medicine published the interim results, which concluded that ravulizumab produced a significantly greater reduction in the protein-to-creatinine ratio than placebo.

Proteinuria is a surrogate marker. The label states that researchers have not established whether Ultomiris slows the decline of kidney function. The trial’s second primary endpoint, kidney function measured as eGFR at week 106, is meant to support traditional approval. Full approval may depend on that result. In other words, the patient would be paying for strong evidence on a lab marker while the evidence on kidney failure itself is still pending.

How One Infusion Turns Into a $14,946 Bill

Ultomiris dosing depends on body weight. Our example patient weighs 75 kilograms, so his maintenance dose is 3,300 milligrams. At the October 2026 Part B payment benchmark, that dose carries about $74,730 in Medicare-allowed drug payment. Once he meets the $283 annual Part B deductible, he owes 20%, which comes to $14,946. If this infusion is his first Part B claim of the year, the deductible raises his share to about $15,172.

Maintenance infusions come every eight weeks after an initial loading dose. Six maintenance infusions at the illustrated rate would produce roughly $89,676 in drug coinsurance alone, before the loading dose. Actual first-year costs depend on when treatment begins and how many infusions fall within the calendar year. There is no out-of-pocket cap on Original Medicare. Right now, the typical retired worker receives $2,095 a month from Social Security, so a single coinsurance bill equals about 7.1 months of that check.

Payment Limits, List Prices and Your Actual Share

The $74,730 figure is an estimate based on Medicare’s October 2026 payment limit, which CMS updates quarterly using drug pricing data. It differs from the list price and from what the infusion site actually bills. Three variables move his real liability:

  • Administration costs: The infusion center or hospital outpatient department bills separately for the infusion service and any facility fee. He owes 20% of those charges too.
  • Coverage requirements: FDA approval doesn’t guarantee payment on every Medicare claim. Treatment must meet applicable Medicare coverage and medical-necessity requirements, and contractors may have additional documentation or billing rules for the new indication.
  • Reduced coinsurance: Each quarter, CMS publishes a list of Part B drugs whose coinsurance drops below 20% under inflation-rebate rules. Check whether Ultomiris is on the current list.

Medigap Underwriting Is the Trap Behind the Bill

Medigap Plan G covers the 20% Part B coinsurance after the deductible. Plan N also covers that coinsurance, although certain office visits and ER visits can carry copays. The catch is timing. Once the six-month Medigap open enrollment window that starts with Part B has closed, insurers in most states can medically screen applicants, and a patient with advancing kidney disease is a likely denial. A handful of states, including New York, Connecticut, Massachusetts and Maine, give broader guaranteed-issue rights. Check your own state’s rules.

Open enrollment runs Oct. 15 through Dec. 7, 2026, and any change takes effect Jan. 1, 2027. If he can’t get Medigap, the in-network out-of-pocket maximum under Medicare Advantage would cap his drug exposure in 2027. The cap could substantially limit his expenses if the Advantage plan covers Ultomiris for his condition and he receives treatment from in-network providers. The tradeoff is real. The plan can require prior authorization for Ultomiris, and switching back to Original Medicare later probably means facing the same Medigap underwriting he would fail today. Coinsurance on a biologic is only one of the surprises Medicare hides inside its sticker price, and we detailed the rest, from IRMAA surcharges to coverage gaps, in a free guide here.

Three Steps Before Treating $15,000 as Your Bill

  1. Get an indication-specific estimate. Ask the infusion site to run a benefits verification for IgA nephropathy, listing dose, billing code and site of care. Request the estimate in writing, with administration and facility fees included.
  2. Compare Advantage plans before December 7. On Medicare Plan Finder, confirm that your nephrologist and infusion center are in network, read each plan’s prior authorization criteria for Ultomiris and note its in-network maximum.
  3. Line up coinsurance help and discuss treatment safety. Medicare beneficiaries generally cannot use manufacturer copay cards, but independent charitable foundations may offer assistance if funding is available. Ultomiris also carries a serious meningococcal infection warning, so ask your nephrologist about required vaccinations and the drug’s safety program before treatment.

Contact [email protected] for any questions or corrections.

Gerelyn Terzo

Gerelyn Terzo is the author of dividend investing handbook "Dividend Investing Strategies: How to Have Your Cake & Eat It Too." A veteran financial journalist, she covers agri-finance for outlets like Global AgInvesting and the broader stock market and personal finance for 24/7 Wall Street. She began at CNBC and later helped launch Fox Business in New York. Gerelyn currently resides in Woodland Park, Colorado and dabbles in nature photography as a hobby.

All articles →